Lansion Biotechnology, a renowned domestic high-tech enterprise specializing in vitro diagnostics, announced the successful closing of nearly RMB 100 million in its Series D2 financing, led by a government fund.

CEC Capital Group served as the exclusive financial advisor for Lansion Biotechnology in this transaction.

After securing a multi-hundred million RMB Series D1 investment from CICC Capital and Dynamic Capital earlier this year, Lansion Biotechnology has received additional capital backing. The funds from this round will be primarily used to bolster the company's presence in both domestic and international markets, accelerating their channel network expansion to better reach end-users.